Pliant reports Q4 2022 net loss $35.1M; positive bexotegrast data, $287.5M raise extends runway to H2 2026

PLIANT THERAPEUTICS, INC.

Bexotegrast 320 mg in IPF Phase 2a showed statistically significant FVC increases at 12 weeks; no drug-related severe AEs.
Closed $287.5M equity offering in Jan 2023; net proceeds $269.9M, extending cash runway into second half of 2026.
Q4 2022 net loss $35.1M ($24.5M prior year); R&D expenses $25.1M, G&A $14.3M.
24-week INTEGRIS-IPF 320 mg data expected Q2 2023; Phase 2b IPF trial initiation mid-2023.
EMA granted Orphan Drug designation for bexotegrast in IPF; Novartis terminated PLN-1474 deal and returned rights.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PLIANT THERAPEUTICS, INC. reported financial results for the fourth quarter ended December 31, 2022.

Period: the fourth quarter ended December 31, 2022
Result: reported results

Exact text from the filing

On March 9, 2023, Pliant Therapeutics, Inc. (the "Company") issued a press release announcing the Company’s financial results for the fourth quarter ended December 31, 2022.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

PLIANT THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001746473-23-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.